Fuji Pharma (4554) FY2026 Q2 Earnings Report

Quick View

Executive Summary

2026 FY Q2 results: Revenue ¥297.2B (YoY +¥56.2B +23.3%), Operating Income ¥44.0B (YoY +¥20.9B +90.8%), Ordinary Income ¥42.6B (YoY +¥20.5B +92.9%), Net Income ¥7.1B (YoY -¥5.7B -44.6%). Operating-stage profitability improved substantially, but Net Income declined YoY due to the recording of special losses ¥35.8B including an investment securities valuation loss ¥35.2B. Operating margin improved to 14.8% from 9.6% a year earlier (+5.2pt), and gross margin also rose to 41.5% (prior 40.9%). SG&A ratio fell to 26.7% (prior 31.5%), and operating leverage worked favorably against revenue growth. Progress against full-year guidance is Revenue 50.1%, Operating Income 71.9%, Ordinary Income 72.5% — core earnings are on track, but Net Income lags at 3.2% due to the one-off loss.

Drivers of Performance

[Revenue] Revenue was ¥297.2B (YoY +23.3%) with robust top-line growth. The Group operates a single Pharmaceuticals Business segment and does not disclose segment breakdowns, but short-term advances received (deferred revenue) increased from ¥0.4B to ¥1.3B year-on-year, indicating steady order trends. Gross margin improved to 41.5% from an estimated 41.0% a year earlier (+0.5pt), suggesting product-mix improvement and effective cost control. Cost of goods sold increased to ¥173.8B (prior ¥142.1B, +22.3%), but the revenue growth outpaced COGS increases.

[Profitability] Operating Income was ¥44.0B (YoY +90.8%), a large rise. SG&A was ¥79.3B (prior ¥75.8B, +4.5%) but SG&A ratio fell to 26.7% (prior 31.5%, -4.8pt) due to revenue growth, so operating leverage contributed. Ordinary Income was ¥42.6B (YoY +92.9%), similarly strong. Non-operating income was ¥1.4B and non-operating expenses were ¥2.8B; interest expense was ¥1.9B (prior ¥1.4B), slightly higher but with minor impact on ordinary-stage results. Pretax income was ¥6.8B (prior ¥17.5B, -61.0%) mainly due to special losses of ¥35.8B (prior ¥4.6B). Breakdown: investment securities valuation loss ¥35.2B, impairment losses ¥3.9B, disaster losses ¥0.0B, etc. Income taxes were -¥0.3B (effective tax rate -4.2%), with an increase in deferred tax assets of ¥13.3B exceeding current tax expense of ¥12.9B, producing a large positive tax effect. As a result Net Income was ¥7.1B (YoY -44.6%). Conclusion: strong revenue-driven operating and ordinary profit growth, but Net Income declined due to temporary special losses.

Key Financial Metrics

[Profitability] Operating margin improved to 14.8% (prior 9.6%, +5.2pt), and gross margin rose to 41.5% (prior est. 41.0%). Operating leverage and product-mix improvement contributed. Net margin fell to 2.4% (prior 5.3%), mainly due to recording special losses ¥35.8B, while recurring earning power strengthened. ROE is 1.4% (prior est. 2.7%) and remains low, reflecting temporary compression of Net Income. [Cash Quality] Operating Cash Flow (OCF) was ¥40.6B (prior ¥21.3B, +90.5%), a large increase. OCF/Net Income is 5.7x, high partly due to non-cash adjustment for the investment securities valuation loss. OCF/EBITDA is 0.63x (EBITDA ¥64.5B = Operating Income ¥44.0B + Depreciation ¥20.6B), which is low. Working capital absorbed cash: Inventory -¥31.3B (DIO 514 days) and Accounts Receivable ¥7.8B (DSO 171 days), resulting in CCC 579 days, extended. Free Cash Flow was ¥20.8B, sufficient to cover dividends ¥6.2B and CapEx ¥9.1B. [Investment Efficiency] Total asset turnover is 0.30x, standard. CapEx/Depreciation is 0.44x, low and potentially below maintenance level, posing a challenge for medium-term growth investment capacity. [Solvency] Equity Ratio is 52.4% (prior 50.2%), improved. Current ratio 168.2%, quick ratio 145.6% — liquidity is healthy. Debt-to-equity ratio is 0.91x, Debt/Capital 29.9% — moderate, but Debt/EBITDA is 3.39x, somewhat high. Short-term borrowings ¥153.0B comprise the bulk of interest-bearing debt and short-term debt ratio is 69.9%, creating a pronounced maturity mismatch and refinancing risk. Interest coverage is 23.3x, indicating strong interest-paying capacity.

Cash Flow Analysis

Operating Cash Flow was ¥40.6B (prior ¥21.3B, +90.5%), with operating cash subtotal (before working capital changes) of ¥52.9B (prior ¥39.2B). Working capital deteriorated sharply: inventories -¥31.3B (inventory increase ¥73.0B, prior ¥65.7B) absorbed cash. Accounts receivable improved by +¥7.8B, but payables contributed only +¥4.0B. Corporate tax payments were -¥10.4B (prior -¥16.5B), decreasing. Investing CF was -¥19.8B, led by CapEx -¥9.1B (prior -¥6.7B) and intangible asset investment -¥9.9B (prior -¥17.3B). Investment pace eased versus prior year, but CapEx is only 0.44x depreciation ¥20.6B, so securing investment capacity remains an issue. Financing CF was +¥13.9B: long-term borrowings raised +¥90.0B exceeded short-term borrowings repayments -¥68.2B, resulting in net increase in funding. Dividend payments were -¥6.2B. Free Cash Flow was ¥20.8B, covering dividends and investment, and cash & deposits increased by ¥36.4B to ¥108.9B (prior ¥72.5B). Improving working capital efficiency and normalizing investment levels are key to strengthening future cash generation.

Quality of Earnings

The decline in Net Income this period is mainly due to special losses ¥35.8B (including investment securities valuation loss ¥35.2B); recurring earning power is strengthened as reflected by Operating Margin 14.8%. Non-operating items are minor: non-operating income ¥1.4B, non-operating expenses ¥2.8B relative to sales. The gap between Ordinary Income ¥42.6B and Net Income ¥7.1B is large, but driven by one-off special losses; pretax income was ¥6.8B while income taxes were -¥0.3B and deferred tax asset increases ¥13.3B produced a sizable positive tax effect. Accrual ratio is -3.4% ((Net Income ¥7.1B – Operating CF ¥40.6B) ÷ Total Assets ¥979.4B), indicating good cash backing of profits. However, OCF/EBITDA at 0.63x is low and working capital deterioration (inventory -¥31.3B) impedes cash conversion. Comprehensive income was ¥17.6B, exceeding Net Income ¥7.1B; components include foreign currency translation adjustments ¥5.5B and valuation differences on securities ¥5.0B, indicating some temporary valuation gains. Recurring quality of earnings is high, but sustained cash generation requires improvement in working capital efficiency.

Outlook & Guidance

Full-year guidance (Revenue ¥592.5B, Operating Income ¥61.2B, Ordinary Income ¥58.8B, Net Income ¥22.4B) progress ratios: Revenue 50.1%, Operating Income 71.9%, Ordinary Income 72.5%, Net Income 3.2%. Operating and ordinary results substantially exceed standard half-year progress (50% at Q2), highlighting a strong first half. Net Income lags materially due to special losses ¥35.8B; achieving full-year Net Income assumes no repeat of one-off losses in H2. Guidance plans YoY growth of Revenue +14.7%, Operating Income +22.6%, Ordinary Income +31.9%; if operating-stage profitability improvements persist, Operating and Ordinary results could beat guidance. Forecast EPS for Net Income is ¥91.54; H1 realized EPS is ¥28.75 (31.4% progress), so H2 recovery in earnings is critical. No revisions to earnings or dividend guidance were made this quarter.

Shareholder Returns

Q2 dividend was ¥23, with full-year dividend forecast ¥26.0 including year-end. H1 EPS ¥28.75 yields a payout ratio of 85.6%, high largely because Net Income was temporarily compressed by special losses. Total dividends relative to Free Cash Flow: dividends approximately ¥6.2B (Total dividends = ¥23 × approx. 26.8 million shares ÷ 2, estimate) with FCF ¥20.8B, giving FCF coverage of 3.4x — ample room. Cash balance increased to ¥108.9B (prior ¥72.5B), maintaining liquidity. If one-off losses drop out and Net Income recovers to forecast ¥22.4B, payout ratio would normalize to 28.4% (¥26 ÷ ¥91.54). Short-term payout ratio is high, but funding capacity is sufficient and dividend sustainability is secured. No buyback announcement; shareholder returns are dividend-centric.

Risk Factors

1. Working capital inefficiency risk: Inventory days 514, Accounts Receivable days 171, CCC 579 days — elongated. Inventory increased +11.1% from ¥65.7B to ¥73.0B. Risks include obsolescence from inventory stagnation and counterparty credit risk from prolonged receivables, which could reduce operating cash generation and strain liquidity. Normalizing working capital is key to sustainable cash generation.

2. Refinancing risk from high short-term debt reliance: Short-term borrowings ¥153.0B are the main component of interest-bearing debt and short-term debt ratio is 69.9%. Cash ¥108.9B cannot cover total short-term debt, highlighting a maturity mismatch. Debt/EBITDA is 3.39x and borrowing dependence is material; interest rate hikes or financing institution responses could pressure liquidity.

3. Medium-term growth risk from suppressed investment levels: CapEx/Depreciation is 0.44x and intangible investment fell from -¥17.3B to -¥9.9B. Investment may fall below maintenance levels, risking insufficient accumulation of production capacity and R&D assets, which could impair competitiveness. In pharmaceuticals, maintaining R&D investment ratios is important; monitor future investment policy.

Industry Benchmark (reference, company estimates)

Profitability & Returns

Operating margin improved markedly to 14.8% from 9.6% a year earlier. Net margin is low at 2.4% due to special losses, but ordinary-stage profitability is healthy.

Growth & Capital Efficiency

Revenue growth rate 23.3% is high.

※ Source: Company compilation

Earnings Highlights

1. Operating-stage profitability improved substantially: Operating Margin 14.8% (prior 9.6%), Gross Margin 41.5% (prior est. 41.0%). Decline in SG&A ratio and operating leverage effects are clear, with progress versus full-year guidance showing Operating Income 71.9% and Ordinary Income 72.5% — indicating upside potential. Product-mix improvement and SG&A efficiency have driven structural improvements in core earnings power.

2. Net Income fell YoY -44.6% due to special losses ¥35.8B (including investment securities valuation loss ¥35.2B), but these are one-off. Ordinary Income rose +92.9%; absent repeated one-offs in H2, Net Income could recover substantially. Net Income progress versus full-year guidance is 3.2%, so H2 performance is critical to full-year achievement.

3. Working capital deterioration (CCC 579 days, Inventory +11.1%) and suppressed investment (CapEx/Depreciation 0.44x) are medium-term concerns. Short-term debt ratio 69.9% and reliance on short-term borrowings are high; improving debt maturity profile should be prioritized. Interest coverage 23.3x shows debt service capacity, but Debt/EBITDA 3.39x indicates somewhat elevated leverage — normalizing inventory/receivables and revising investment levels are prerequisites for sustainable growth.

---

This report was auto-generated by AI analyzing XBRL financial statement data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are company-compiled reference information based on public financial data. Investment decisions are your responsibility; consult a professional advisor as needed.

---

AI Financial Analysis

Executive Summary

FY2026 Q2 was operationally very strong, but statutory earnings were materially reduced by a large extraordinary valuation loss. Revenue rose 23.3% year on year to ¥29.72bn. Operating income increased 90.8% to ¥4.40bn, substantially outpacing sales growth. Ordinary income also grew 92.9% to ¥4.26bn. The operating margin expanded to 14.8% from 9.6% in the prior-year period, a 520bp improvement. Gross margin improved to 41.5% from 41.0%, a 50bp expansion, indicating that most of the operating-margin improvement came from operating leverage rather than gross-margin expansion alone. SG&A increased only 4.6% year on year to ¥7.94bn, far below the 23.3% sales increase. EBITDA rose to ¥6.45bn and the EBITDA margin reached 21.7%. However, a ¥3.58bn extraordinary loss, principally including a ¥3.52bn loss on valuation of investment securities, reduced profit before tax to ¥0.68bn. Consequently, net income declined 44.6% year on year to ¥0.71bn despite the sharp improvement in operating profit. The net margin was therefore only 2.4%, compared with 5.3% a year earlier. Operating cash flow was robust at ¥4.06bn and exceeded net income by 5.69x, reflecting the non-cash nature of the extraordinary loss and favorable operating cash generation. Free cash flow was positive at ¥2.08bn after ¥0.91bn of capital expenditures. The balance sheet retains healthy headline liquidity, with a current ratio of 168.2% and quick ratio of 145.6%. Nevertheless, ¥15.30bn of short-term loans account for 69.9% of interest-bearing debt, making refinancing management a central financial consideration. Management retained its full-year forecast, and Q2 operating-income progress of 71.9% is well ahead of the standard 50% midyear pace. The central issue for the second half is whether the strong operating momentum can continue while the company manages working-capital intensity, short-term funding concentration, and the earnings effect of investment-security valuations.

Profitability Analysis

The reported annualized DuPont ROE is 2.8%, decomposed into a 2.4% net profit margin, 0.607x asset turnover, and 1.91x financial leverage. The weakest DuPont component is the net margin, not asset utilization or leverage. The net-margin outcome does not reflect core operating profitability: EBIT margin was 14.8% and operating income increased 90.8% year on year. Instead, the ¥3.58bn extraordinary loss, including ¥3.52bn of investment-security valuation loss, compressed profit before tax to ¥0.68bn and reduced net income to ¥0.71bn. This drove an unusually low interest-burden ratio of 0.155, as the ratio uses profit before tax after extraordinary items relative to EBIT; it should not be interpreted as ¥3.72bn of cash interest expense. Actual reported interest expense was ¥0.19bn, and EBIT-to-interest coverage was 23.27x, while EBITDA interest coverage was 34.14x. Gross margin improved by 50bp to 41.5%, while the 520bp operating-margin expansion to 14.8% was much larger. SG&A rose 4.6%, versus 23.3% revenue growth, producing favorable operating leverage and demonstrating good expense discipline in the first half. EBITDA margin of 21.7% supports the view that underlying profitability was stronger than reported net income. Financial leverage of 1.91x and D/E of 0.91x are moderate rather than aggressive, so leverage was not the primary driver of reported ROE. The sustainability of the operating-margin improvement will depend on continued sales growth and the ability to preserve SG&A discipline; the extraordinary valuation loss is non-recurring in presentation but signals potential volatility in investment-related earnings.

Growth Assessment

Revenue growth of 23.3% to ¥29.72bn was accompanied by operating-income growth of 90.8%, indicating strong incremental profitability. Gross profit increased 24.7% to ¥12.33bn, slightly faster than revenue, supporting the modest gross-margin expansion. The much faster operating-income growth reflects a favorable fixed-cost absorption effect, as SG&A growth remained limited to 4.6%. The group operates as a single pharmaceutical segment, making the pharmaceutical business the core business. Full-year revenue guidance is ¥59.25bn, and Q2 cumulative sales represent 50.2% of the full-year target, broadly in line with the standard 50% first-half pace. Full-year operating-income guidance is ¥6.12bn, with Q2 cumulative progress of 71.9%, 21.9 percentage points above the standard midyear pace. Ordinary-income progress is similarly high at 72.5% against full-year guidance of ¥5.88bn. In contrast, net-income progress is only 31.8% against the ¥2.24bn full-year forecast because the first-half extraordinary valuation loss materially reduced statutory earnings. The unchanged forecast implies management expects core profitability to remain supportive while absorbing the first-half non-operating and extraordinary effects. Intangible assets of ¥13.73bn, equal to 14.0% of assets, are meaningful but remain below the 20% benchmark associated with a more IP-heavy asset profile. Future growth quality should be assessed through the durability of sales growth, the degree of recurring operating leverage, and whether investment-valuation losses recur.

Financial Health

Liquidity is sound on reported balance-sheet measures. Current assets of ¥54.32bn exceed current liabilities of ¥32.29bn, resulting in a current ratio of 168.2%. The quick ratio is also healthy at 145.6%, indicating that liquidity is not dependent on inventory liquidation. Working capital totals ¥22.02bn. Cash and deposits increased 50.3% year on year to ¥10.89bn, strengthening immediate liquidity. However, short-term loans are ¥15.30bn, exceeding cash by ¥4.41bn; cash covers only 0.71x of short-term debt. Short-term borrowings account for 69.9% of the ¥21.90bn interest-bearing debt balance, which creates a maturity mismatch risk even though current assets exceed current liabilities. This directly addresses the refinancing-risk alert: the concern is the concentration of debt maturities rather than a current liquidity-ratio breach. Long-term loans of ¥6.60bn provide some duration, but the funding structure remains weighted toward short-term facilities. D/E of 0.91x is within the conservative sub-1.0x benchmark, and debt-to-capital of 29.9% is below the 40% investment-grade reference level. Debt/EBITDA of 3.39x is above the 2.5x investment-grade benchmark but below the 4.0x high-yield warning threshold. Strong EBITDA interest coverage of 34.14x and EBIT interest coverage of 23.27x indicate that current interest-servicing capacity is robust. Investment securities declined 54.9% year on year to ¥2.30bn, largely consistent with the ¥3.52bn valuation loss recorded in extraordinary items and reducing the carrying value of this asset pool. Deferred tax assets were ¥3.44bn, representing a meaningful asset whose realization is linked to future taxable profitability.

Notable B/S Changes

Investment securities: -¥2.80bn (-54.9%) to ¥2.30bn - the decline is consistent with the ¥3.52bn investment-security valuation loss recognized in extraordinary items; it reduced statutory earnings and highlights residual market-value exposure. Cash and deposits: +¥3.64bn (+50.3%) to ¥10.89bn - stronger cash balances improve liquidity, although they remain below ¥15.30bn of short-term loans. Total equity: +¥4.46bn (+9.5%) to ¥51.36bn - equity increased despite lower net income, supported by accumulated other comprehensive income; the capital base supports a moderate 0.91x D/E ratio.

Cash Flow Quality

Operating cash flow was ¥4.06bn, up from ¥2.13bn in the prior-year period, and was substantially above net income of ¥0.71bn. The OCF/net-income ratio of 5.69x is strong on its face and does not indicate an accrual-quality shortfall. The negative 3.4% accruals ratio also supports cash-backed earnings quality. However, the unusually large OCF/net-income gap is principally explained by the non-cash ¥3.58bn extraordinary loss, especially the ¥3.52bn investment-security valuation loss, rather than by an equivalent expansion in recurring cash profitability. Cash conversion, measured as OCF/EBITDA, was 0.63x and triggers the low-cash-conversion alert because less than 70% of EBITDA converted into operating cash flow. Inventory increased by ¥3.13bn and trade receivables increased by ¥0.78bn in the operating cash-flow bridge, absorbing cash despite the positive reported operating cash flow. The reported high-receivable-days alert of 85 days indicates elevated cash collection duration relative to the 60-day benchmark. The reported inventory alerts indicate high inventory duration, with reported measures of 257 days and 77 days both above their respective alert thresholds. These inventory alerts point to substantial working-capital commitment in pharmaceutical production and distribution, with finished goods of ¥7.30bn and raw materials of ¥13.47bn. The reported cash-conversion-cycle alert of 290 days further highlights that operating cash is tied up for an extended period before collection. This is a material operational risk because a further buildup in receivables or inventories could weaken cash conversion even if accounting profit remains strong. Free cash flow was positive at ¥2.08bn after ¥0.91bn of capital expenditures. CapEx/depreciation was 0.44x, below the 0.7x threshold and triggering both underinvestment alerts. The root concern is that capital spending is replacing less than half of the ¥2.06bn depreciation and amortization charge, which can constrain manufacturing renewal and capacity investment if sustained. In the near term, low CapEx supports free cash flow, but for a pharmaceutical manufacturer it warrants monitoring for possible deferred maintenance, capacity, or quality-system investment needs.

Dividend Sustainability

The interim dividend is ¥23.00 per share. Based on first-half net income, the calculated interim payout ratio is 85.6%, which is elevated relative to the 60% sustainability benchmark. This ratio is distorted upward by the extraordinary valuation loss that reduced first-half net income, while underlying operating cash flow remained strong. Free cash flow of ¥2.08bn covers the calculated interim dividend cash requirement by 3.41x, providing strong cash coverage. The unchanged full-year dividend forecast is ¥49.00 per share. Against full-year forecast EPS of ¥91.54, the implied full-year dividend payout ratio is approximately 53.5%, which is within the stated sustainable benchmark. Accordingly, the announced full-year dividend appears supportable by forecast earnings and first-half free cash flow, provided operating cash generation remains resilient. The main sensitivity is not current interest expense, given strong coverage, but the potential need to refinance short-term borrowings and finance working-capital requirements. Continued low capital expenditure would support near-term distribution capacity, although persistently low reinvestment may not be optimal for long-run dividend resilience.

Risk Assessment

Business risks include Working-capital intensity is high: reported receivable days of 85 and reported inventory-duration alerts of 257 days and 77 days indicate extended cash lock-up in receivables and pharmaceutical inventories., The reported 290-day cash conversion cycle creates sensitivity of operating cash flow to collection timing, inventory planning, and demand forecasting., For a pharmaceutical manufacturer, inventory accumulation also carries product-obsolescence, expiry-date, regulatory-compliance, and manufacturing-quality risks., Operating-profit outperformance relies partly on favorable operating leverage; slower sales growth could limit further margin expansion if SG&A normalizes., The ¥3.52bn investment-security valuation loss demonstrates exposure to market-value volatility outside core pharmaceutical operations..

Financial risks include Short-term loans of ¥15.30bn account for 69.9% of interest-bearing debt, creating refinancing risk and a maturity mismatch because cash of ¥10.89bn covers only 0.71x of short-term debt., Debt/EBITDA of 3.39x is manageable but above the 2.5x investment-grade reference point, leaving less flexibility if EBITDA or cash conversion weakens., The low 0.63x OCF/EBITDA cash-conversion ratio indicates that EBITDA does not fully translate into cash in the current period., CapEx/depreciation of 0.44x could preserve short-term cash but may increase future capital-renewal requirements if maintained., Deferred tax assets of ¥3.44bn depend on the availability of future taxable income for realization..

Key concerns include Highest priority: manage the combination of long cash-conversion-cycle metrics and short-term debt concentration, as a deterioration in working capital could increase refinancing dependence., High priority: distinguish recurring operating improvement from statutory profit volatility caused by investment-security valuation losses., Moderate priority: monitor whether low capital expenditure reflects temporary timing or sustained underinvestment in production assets and intangible capabilities., Moderate priority: track the full-year net-income forecast, since first-half progress is only 31.8% despite operating-income progress of 71.9%..

Investment Implications

Key takeaways include Core earnings improved sharply: revenue increased 23.3%, operating income increased 90.8%, and operating margin expanded 520bp to 14.8%., Reported net income fell 44.6% because of a ¥3.58bn extraordinary loss, principally a ¥3.52bn investment-security valuation loss, rather than deterioration in operating profit., The full-year operating-income forecast appears conservative relative to 71.9% first-half progress, while net-income delivery depends on the absence of further exceptional charges., Operating cash flow and free cash flow were positive, but 0.63x cash conversion and elevated reported receivable, inventory, and cash-cycle metrics require close monitoring., Balance-sheet leverage is moderate, but the 69.9% short-term-debt ratio makes debt refinancing and liquidity management important..

Metrics to watch include Revenue growth and operating-margin retention relative to the 14.8% Q2 cumulative margin, Full-year operating-income progress versus ¥6.12bn guidance and net-income progress versus ¥2.24bn guidance, Operating cash flow/EBITDA conversion, currently 0.63x, Receivable days, inventory duration, and the reported 290-day cash conversion cycle, Short-term loan balance, cash/short-term-debt coverage, and debt/EBITDA, Capital expenditure relative to depreciation, currently 0.44x, Further valuation movements in investment securities and related extraordinary gains or losses.

Regarding relative positioning, The company presents stronger underlying profitability than its 2.4% reported net margin and 2.8% annualized ROE suggest, because extraordinary investment-security valuation losses obscured a 14.8% EBIT margin and 21.7% EBITDA margin. Its liquidity ratios and interest coverage are solid, but working-capital efficiency and short-term debt concentration are less favorable features than the headline balance-sheet metrics indicate.